Table 1:
Summary of the published CD30 CAR-T cells studies
| Study | No. of HL Patients | Median Age (Range), y | No. of Patients with Prior BV (%) | LDC | Costimulatory Endodomain (Vector) | Range of CAR-T Cells Ooses | Response % (n) | CRS & ICANS %(n) | |
|---|---|---|---|---|---|---|---|---|---|
| C. Wang et al,17 | 2017 | 17 | 31 (13–55) | 423 | GEMC (n = 8) Flu + Cy (n = 5) PC (n = 4) Others (n = 4) |
4–1BB (Lenti virus) | 1.1–2.1 × 107 cells/kg | ORR 35%6
PR 35%6 |
CRS. all grades: 100%17
CRS. grade ≥3: 0% ICANS. all grades: 0% ICANS. qrade ≥3: 0% |
| Ramos et al,18 | 2017 | 7 | 31 (20–65) | 5 (71) | None | CD28 (γ-retrovirus) | 0.2–2.0 × 108 cells/m2 | ORR 29%2
CR 29%2 a |
CRS. all grades: 0% CRS. grade ≥3: 0% ICANS. all grades: 0% ICANS. qrade ≥3: 0% |
| Ramos et al,19 | 2021 | 42 | 35 (17–69) | 38 (90) | Flu + Cy (n = 17) Benda-Flu (n = 17) Benda (n = 8) |
CD28 (γ-retrovirus) | 0.2–2.0 × 108 cells/m2 | ORR 62% (23/37)b
CR 51% (19/37) PR 11% (4/37) |
CRS. all grades: 24%10
CRS. grade ≥3: 0% ICANS. all grades: 0% ICANS. grade ≥3: 0% |
Abbreviations: Benda, bendamustine; BV, brentuximab vedotin; CR, complete response; CRS. cytokine release syndrome; Flu+Cy, fludarabine + cyclophosphamide; GEMC, gemcitabine + epirubicin + mustargen + cyclophosphamide; HL, Hodgkin lymphoma; ICANS, immune effector cell-associated neurotoxicity syndrome; LDC. lymphodepleting chemotherapy; ORR, overall response rate; PC, nab-paclitaxel + cyclophosphamide; PR, partial response.
a
One patient had no active disease but maintained remission after CAR-Tcells.
b
Thirty-seven patients who had active disease before infusion were included in the ORR calculation.